ORBIMED ADVISORS LLC 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-14 8:49 pm Unchanged | 2025-05-12 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 9,785,423 12.200% | 0 (Unchanged) | Filing |
| 2025-05-01 9:20 pm Purchase | 2025-04-29 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 9,785,423 13.800% | 2,841,769 (+40.93%) | Filing |
| 2024-05-08 7:55 pm Unchanged | 2024-05-06 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 6,943,654 11.100% | 0 (Unchanged) | Filing |
| 2021-11-03 3:03 pm Unchanged | 2021-11-02 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 6,943,654 14.900% | 0 (Unchanged) | Filing |
| 2021-09-22 5:21 pm Sale | 2021-09-20 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 6,943,654 16.400% | -1,109,644 (-13.78%) | Filing |
| 2021-08-04 5:21 pm Unchanged | 2021-08-02 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 8,053,298 19.000% | 0 (Unchanged) | Filing |
| 2021-02-17 5:08 pm Purchase | 2021-02-17 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 8,053,298 21.980% | 1,285,714 (+19.00%) | Filing |